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Endothelial function in proteinuric renal disease. Nephrotic- THE L-ARGININE NITRIC OXIDE PATHWAY
range proteinuria is associated with a several-fold increase risk Endothelium-derived NO is a lipophilic gas that isof cardiovascular infarction. This increased risk is accompanied
produced by the endothelial isoform of NO synthaseby endothelial dysfunction, which is not related to increased
(eNOS). This enzyme incorporates molecular oxygenblood pressure and is not correctable by acute administration
of l-arginine. The latter is in direct contrast to what has been into the substrate l-arginine. eNOS is a constitutively
found in patients with primary hypercholesterolemia, sug- expressed enzyme that is present as a homodimer. The
gesting that either hypoalbuminemia itself or other aspects NOS III also undergoes post-translational acylation
of the dyslipidemia characteristic of the nephrotic syndrome
(myristoylation and palmitoylation), which appears toimpair endothelial function. Lysophosphatidylcholine (lyso-
be essential for its activity by anchoring the enzyme toPC) is formed during oxidative modification of cholesterol, and
the cell membrane [3]. eNOS binds to distinct domainslyso-PC in oxidized low-density lipoprotein (LDL) is responsi-
ble for reduced endothelial function in vitro. However, in the of the plasma membrane, called caveoli, which serve as
circulation, lyso-PC is tightly bound to albumin. Indeed, the sites for the sequestration of receptor-coupled signaling
addition of albumin can restore endothelial function, which was proteins and which are tethered to the cytoskeleton. The
previously disturbed by lyso-PC. Hypoalbuminemia induces a
protein–protein interaction of eNOS with the scaffoldingshift in lyso-PC to lipoproteins, notably LDL, and to erythro-
domain of caveolin-1, a structural protein of caveoli, maycytes. The latter directly induces a reduction in deformability
inhibit activation of the enzyme. Stimulation of (mostlythat can also be corrected by the addition of albumin. Hypoal-
buminemia may disturb endothelial function, either by directly Gi-protein–coupled) receptors and shear stress can acti-
affecting Gi-protein–dependent signal transduction or indi- vate the enzyme, possibly by also affecting the interac-
rectly by changing the configuration of the cell membrane. tion of eNOS with caveolin-1. After production of NO,
Such a change in cell membrane configuration will disturb
the bioavailability of NO is largely determined by thebinding of ligands to receptors and of endothelial nitric oxide
reaction with superoxide anion. Interestingly, it has re-(NO) synthase to caveolin. However, other pathways have
cently been shown that eNOS is a dual enzyme thatbeen suggested, such as stimulation by lyso-PC of vasoconstric-
tion mediated by protein kinase C. It remains to be shown simultaneously produces NO as well as superoxide [4].
whether lipid-lowering and antiproteinuric strategies have in- Under pathophysiological conditions, a shift occurs from
dependent positive effects on endothelial function in nephrotic NO to superoxide production by the heme domain of
subjects.
eNOS [5], which may result in the formation of a strong
oxidant, peroxynitrite. This shift is related to a reduced
bioavailability of the essential cofactor tetrahydrobiop-
Patients with renal disease are characterized by a large terin (discussed earlier here).
increase in cardiovascular morbidity and mortality [1].
In the last two decades, endothelial dysfunction has
DYSLIPIDEMIA ANDemerged as potential final common pathway, which may
ENDOTHELIAL DYSFUNCTIONpromote systemic atherosclerotic as well as renal disease
progression. In particular, endothelium-derived nitric Increased low-density lipoprotein (LDL) cholesterol
oxide (NO) has been shown to be intimately involved is invariably associated with impaired NO-mediated va-
in both the antiatherogenic properties of the endothe- sodilation [6]. Other lipid fractions may also affect endo-
lium and hemodynamic regulation of systemic and renal thelial function. Thus, in patients with familial combined
perfusion [2]. hyperlipidemia, we observed an inverse correlation be-
tween intermediate-density lipoprotein cholesterol and
NO activity [7]. Most data suggest that reduced NO
Key words: albumin, cardiovascular, dyslipidemia, nitric oxide, lipids. availability in dyslipidemia is due to increased degrada-
tion of NO rather than decreased production [2]. Indeed, 1999 by the International Society of Nephrology
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endothelial dysfunction in vivo can be improved by the increased synthesis [15]. Notably, both triglyceride-rich
lipoproteins and increased LDL cholesterol have beenoxygen radical scavenger vitamin C and the xanthine
oxidase inhibitor allopurinol. Recently, we have demon- associated with impaired NO-mediated vasodilation
[6, 7]. Whereas increasing substrate availability by infu-strated that NO production in hypercholesterolemic pa-
tients, assessed with a stable isotope technique, is indeed sion of l-arginine improves NO-dependent vasodilation
in hyperlipidemia [6, 10], l-arginine has no effect on thenot significantly different from that in matched (normo-
cholesterolemic) controls [8]. impaired endothelial response in nephrosis (Fig. 1) [14].
These findings suggest that mechanisms involved in en-Increased oxygen radical stress may originate from
NOS as well as other enzyme systems, such as xanthine dothelial dysfunction in nephrosis differ from other
forms of endothelial dysfunction, as can be observed inoxidase. Superoxide production by endothelial in vitro
NOS is greatly diminished on suppletion of tetrahydro- hyperlipidemic patients. This may have two explana-
tions: Either the lipoprotein composition is different dur-biopterin [4]. Simultaneously, tetrahydrobiopterin in-
creases NO production, as assessed with l-arginine– ing hypoalbuminemia, or endothelial dysfunction in ne-
phrosis is directly related to hypoalbuminemia.l-citrulline conversion assay [4]. Interestingly, it has re-
cently been demonstrated that oxidized LDL cholesterol
decreases expression of GTP-cyclohydrolase-I, the rate-
EFFECT OF HYPOALBUMINEMIA
limiting enzyme for tetrahydrobiopterin synthesis [9]. In
ON HYPERLIPIDEMIA
line with these in vitro phenomena, impaired NO activity
Lysophosphatidylcholine (lyso-PC) is formed duringin hypercholesterolemia in vivo can be ameliorated by
oxidative modification of cholesterol [16]. Markedly in-suppletion of tetrahydrobiopterin [10].
creased amounts of lyso-PC have been measured in oxi-Increasing substrate availability for NOS by l-arginine
dized LDL, and the inhibition of endothelial relaxationsuppletion has been shown to improve NO availability,
induced by oxidized LDL cholesterol in vitro could beas assessed by NO-mediated vasodilation [6, 10] and
ascribed to lyso-PC [17, 18]. Lyso-PC is tightly bounddecreased development of atherosclerosis in hypercho-
by albumin [19]. We found increased levels of lyso-PClesterolemic animals [11]. Putative mechanisms contrib-
in the LDL fraction in both hypoalbuminemic nephroticuting to this ameliorative effect of l-arginine in hyper-
rats and nonproteinuric analbuminemic rats [20]. In-cholesterolemia include the presence of endogenous
creased lyso-PC levels were also present in LDL choles-inhibitors of l-arginine, impaired cellular uptake of
terol of hypoalbuminemic nephrotic patients [14]. Wel-arginine, or decreased affinity of NOS for l-arginine.
recently discovered that in normolipidemic patients withInterestingly, tetrahydrobiopterin has been shown to in-
severe hypoalbuminemia, high LDL-lyso-PC levels arecrease substrate affinity of NO synthase for l-arginine
related to hypoalbuminemia, rather than to hyperlipid-[12]. In agreement, after suppletion of tetrahydrobiop-
emia per se [21] (Fig. 2). Hence, in addition to the effectsterin, l-arginine had no further ameliorative effect on
of hyperlipidemia per se, the hypoalbuminemia in ne-endothelial function in hypercholesterolemic patients [10].
phrosis results in diminished binding of lyso-PC to albu-
min, leading to sequestration of lyso-PC in lipoproteins
ENDOTHELIAL DYSFUNCTION IN and possibly in other compartments.
PROTEINURIC PATIENTS One such compartment is the erythrocyte. Deform-
ability of erythrocytes is a crucial characteristic for ade-Nephrotic range proteinuria is associated with a five-
fold to sixfold increased risk of cardiovascular infarction quate microvascular perfusion, whereas reduced eryth-
rocyte deformability may increase platelet adhesion in[13]. This increased risk is accompanied by an impaired
NO defense system in proteinuria in nephrotic patients conduit vessels. In nephrotic patients, erythrocyte de-
formability is decreased [22]. In Nagase analbuminemic[14]. Increased blood pressure is one of the factors that
could contribute to endothelial dysfunction in nephrosis. rats (NAR), similar abnormalities were found, whereas
decreased deformability could be corrected by the addi-However, non-nephrotic glomerulonephritis patients
had normal NO activity, despite blood pressure levels tion of albumin. Lyso-PC levels were increased in NAR
erythrocyte membranes, whereas lyso-PC content inequal to that found in nephrotic patients [14]. Hence,
blood pressure elevation can be excluded as causative erythrocyte membranes decreased after the addition of
albumin [23]. Accordingly, the addition of lyso-PC sig-factor for endothelial dysfunction in these patients. An-
other hallmark of nephrosis is dyslipidemia, consisting nificantly enhanced erythrocyte rigidity only when added
to analbuminemic NAR plasma, whereas no such effectof increased cholesterol as well as increased triglyceride
levels. The increase in triglyceride-rich lipoproteins is could be observed when added to control plasma. Over-
all, these experiments support the concept that hypoal-caused by a decreased fractional catabolic rate in ne-
phrotic patients [15]. In contrast to very LDL cholesterol, buminemia contributes to an increase in erythrocyte
lyso-PC content, which subsequently results in changesincreased LDL cholesterol results predominantly from
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Fig. 1. Effect of L-arginine suppletion on en-
dothelium-dependent vasodilatation. (Left) In
nephrosis, serotonin-induced NO-mediated vas-
odilation is impaired compared with controls.
l-arginine infusion has no effect on endothe-
lium-dependent vasomotion. (Right) In famil-
ial hypercholesterolemia, serotonin-induced
NO-mediated vasodilation is improved signifi-
cantly upon coinfusion of L-arginine. M/C ra-
tio: ratio of forearm blood flow in measure-
ment/control arm [6, 14].
Fig. 2. Oxidation of lipoproteins such as
LDL results in the formation of lyso-PC. Al-
bumin and HDL (through paroxenase) can
deplete LDL from lyso-PC. From this concept,
lyso-PC enrichment during hypoalbuminemia
can be postulated.
of membrane rigidity. Based on these findings, we ex- affects the binding of the eNOS to the plasma membrane,
which is a prerequisite for normal NO function.trapolated this concept to endothelial cells.
The addition of albumin causes a reduction of lyso-PC After incubation of aortic rings in human serum albu-
min (HAS; 50 g/liter), tenfold higher concentrations ofuptake into cultured endothelial cells [24]. Exposure of
lyso-PC caused a dose-dependent decrease in acetylcho- lyso-PC were needed to obtain a similar blockade of
acetylcholine-induced relaxation. Moreover, after prein-line-induced relaxation, whereas the endothelium-inde-
pendent nitroprusside-induced vasodilatory response re- cubation of the rings with lyso-PC, HSA could restore
the acetylcholine-induced vasorelaxation in vitro [26].mained unaffected (abstract; Joles et al, J Am Soc
Nephrol 8:332A, 1997). The degree of impairment of These observations lend further support to the hypothe-
sis that hypoalbuminemia contributes directly to dis-endothelium-dependent vasorelaxation occurred in a
time-dependent fashion, suggesting that lyso-PC has to turbed endothelial function in the nephrotic syndrome.
It must be pointed out that lyso-PC may also affectpenetrate into a compartment to exert its inhibitory ef-
fect. Lyso-PC inhibits Gi-protein–dependent signal trans- endothelial function by NOS-unrelated phenomena.
Low levels of lyso-PC stimulate protein kinase C (PKC)duction pathways. Several receptors responsible for acti-
vation of NOS, such as serotonin, a2-adrenergic agonists, activity [26]. PKC causes sustained vasoconstriction
upon stimulation of agonists such as phenylephrine, an-and thrombin are Gi-protein dependent. Lyso-PC causes
a selective uncoupling of the receptor to the Gi protein, giotensin, and thrombin. PKC is also associated with
increased superoxide production, which may interfereas the response to direct activation of the Gi-protein by
mastoporan was unaffected by lyso-PC [25]. It is unclear with NO bioavailability, as explained earlier here. Fur-
thermore, lyso-PC has been suggested to cause specificwhether lyso-PC has a direct effect on the receptor-Gi-
protein complex or an indirect effect by changes in the disturbances in endothelial function in the nephrotic syn-
drome. Thus, Ohgushi et al observed that endothelialmobility of proteins in the lipid bilayer. In addition, one
could speculate that lyso-PC accumulation in membranes relaxation mediated by the calcium ionophore A23187
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6. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascularwas not disturbed in porcine coronary rings and rabbit
function in the forearm of hypercholesterolaemic patients off and
aorta strips exposed to lyso-PC [18], whereas relaxation on lipid-lowering medication. Lancet 346:467–471, 1995
7. Stroes ESG, de Bruin TWA, Valk HW, Erkelens DW, Bangato this calcium ionophore was diminished in aortic rings
JD, van Rijn HJ, Koomans HA, Rabelink TJ: NO-activity infrom rats with adriamycin-induced nephrosis [27]. Be-
familial combined hyperlipidemia; potential role of cholesterol
cause acute exposition to lyso-PC was 40 minutes of remnants. Cardiovasc Res 36:445–452, 1997
8. Wever R, Boer P, Stroes ESG, Hijmering M, Verhaar M, Koo-preincubation, whereas nephrosis had been present for
mans HA, Rabelink TJ: Different mechanisms of endothelial dys-approximately 40 days, it remains to be established
function between hypercholesterolemia and renal failure. Arter
whether this difference merely reflects varying incuba- Thromb Vasc Biol (in press)
9. Dulak J, Polus M, Guevara I, Hartwich J, Dembinska-Kiec A:tion times of lyso-PC.
Regulation of inducible nitric oxide synthase and GTP cyclohydro-
lase I gene expression by ox-LDL in rat vascular smooth muscle
cells. J Physiol Pharmacol 4:689–697, 1997
IMPLICATIONS FOR THERAPY 10. Stroes ESG, Kastelein JJ, Cosentino F, Erkelens DW, Wever
R, Koomans HA, Luscher TF, Rabelink TJ: TetrahydrobiopterinWhereas the clinical benefit of lipid-lowering therapy restores endothelial function in hypercholesterolemia. J Clin In-
to reduce the cardiovascular risk in both primary as well vest 99:41–46, 1997
11. Boger RH, Bode-Boger SM, Brandes RP, Phivtong-Ngam L,as secondary prevention has been demonstrated in re-
Bohme M, Nafe R, Mugge A, Frohlich JC: Dietary L-argininecent population trials, the effect of lipid lowering per se reduces the progression of atherosclerosis in cholesterol fed rab-
on both endothelial dysfunction as well as cardiovascular bits: Comparison with lovastatin. Circulation 96:1282–1290, 1997
12. Nishimura JS, Martasek P, McMillan K, Salerno JC, Liu Q,events in renal and (chronic) proteinuric patients re-
Gross SS, Masters BSS: Modular structure of neuronal nitric
mains to be established. Thus far, pravastatin resulted oxide synthase: Localization of the arginine binding site and modu-
in an increase in renal plasma flow in nephrotic patients, lation by pterin. Biochem Biophys Res Commun 210:288–294, 1995
13. Ordonnez JD, Hiatt RA, Killebrew EJ, Fireman BH: The in-indicating that cholesterol lowering may improve hemo-
creased risk of coronary heart disease associated with the nephrotic
dynamics [28]. However, attention should probably not syndrome. Kidney Int 44:638–642, 1992
14. Stroes ESG, Joles JA, Chang PC, Koomans HA, Rabelink TJ:only focus on normalization of lipid levels, but also at
Impaired endothelial function in patients with nephrotic rangechanging the unfavorable lipid profile, comprising an
proteinuria. Kidney Int 48:544–550, 1995
increased lyso-PC content. Moreover, our data suggest 15. Sain-van der Velden MGM, Kaysen GA, Barrett HA, Stel-
laard F, Gadellaa MM, Voorbij HAN, Reijngoud D-J, Rabe-that reduction of proteinuria and restoration of hypoal-
link TJ: Increased VLDL in nephrotic patients results from abuminemia may have a specific beneficial effect on endo- decreased catabolism while increased LDL results from increased
thelial function in the nephrotic syndrome. synthesis. Kidney Int 53:994–1001, 1998
16. Parthasarathy S, Steinbrecher UP, Barnett J, Witztum JL,
Steinberg D: Essential role of phospholipase A2 activity in endo-
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